Literature DB >> 28658842

A Case Series of Young Patients with Completely Reversed Severe Pulmonary Hypertension.

Aniketh Vijay Balegadde1, Vikrant Vijan2, Rajesh Thachathodiyl3.   

Abstract

Pulmonary Arterial Hypertension (PAH) is a progressive symptomatic disorder, which may ultimately lead to death if left untreated. Although majority of PAH cases are idiopathic, pulmonary hypertension resulting due to certain underlying conditions are also observed frequently. In such cases, it becomes essential to identify any potentially treatable or reversible causes for PAH. There have been significant advances in the medical management of PAH and various medicines have been approved by US Food and Drug Administration (FDA) for various stages of PAH. With these therapies, there can be varying degrees of improvement in the pulmonary artery pressures and hemodynamic profile. Therefore, physiologic reversal can and does occur, sometimes to the point of normalization. We hereby present three such cases of severe PAH in patients below 50 years of age due to various aetiologies like left heart disease, isolated unilateral absence of right pulmonary artery with hypoplastic right lung and factor V Leiden mutation associated pulmonary thromboembolism, all of whose pulmonary artery pressures are completely normalised with adequate treatment of the underlying disease and with optimised medications for PAH, ultimately leading to tapering and stoppage of PAH medications.

Entities:  

Keywords:  Factor V Leiden; Hypokinesia; Hypoplastic right lung; Left ventricle; Medical management; Pulmonary artery pressure; Pulmonary thromboembolism; Right ventricle

Year:  2017        PMID: 28658842      PMCID: PMC5483744          DOI: 10.7860/JCDR/2017/21942.9914

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  5 in total

Review 1.  Treatment of pulmonary arterial hypertension.

Authors:  Marc Humbert; Olivier Sitbon; Gérald Simonneau
Journal:  N Engl J Med       Date:  2004-09-30       Impact factor: 91.245

Review 2.  Reversible or irreversible remodeling in pulmonary arterial hypertension.

Authors:  Seiichiro Sakao; Koichiro Tatsumi; Norbert F Voelkel
Journal:  Am J Respir Cell Mol Biol       Date:  2009-12-11       Impact factor: 6.914

Review 3.  Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease.

Authors:  L S Howard
Journal:  Eur Respir Rev       Date:  2011-12

4.  Impaired apoptosis of pulmonary endothelial cells is associated with intimal proliferation and irreversibility of pulmonary hypertension in congenital heart disease.

Authors:  Marilyne Lévy; Christelle Maurey; David S Celermajer; Pascal R Vouhé; Claire Danel; Damien Bonnet; Dominique Israël-Biet
Journal:  J Am Coll Cardiol       Date:  2007-02-05       Impact factor: 24.094

5.  Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease.

Authors:  David M Smadja; Pascale Gaussem; Laetitia Mauge; Dominique Israël-Biet; Françoise Dignat-George; Séverine Peyrard; Gabriella Agnoletti; Pascal R Vouhé; Damien Bonnet; Marilyne Lévy
Journal:  Circulation       Date:  2009-01-12       Impact factor: 29.690

  5 in total
  2 in total

1.  Evidence supporting a role for circulating macrophages in the regression of vascular remodeling following sub-chronic exposure to hemoglobin plus hypoxia.

Authors:  Vijaya Karoor; Delaney Swindle; David I Pak; Derek Strassheim; Mehdi A Fini; Edward Dempsey; Kurt R Stenmark; Kathryn Hassell; Rachelle Nuss; Paul W Buehler; David C Irwin
Journal:  Pulm Circ       Date:  2021-11-05       Impact factor: 3.017

2.  Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension.

Authors:  Sachindra R Joshi; Jun Liu; Troy Bloom; Elif Karaca Atabay; Tzu-Hsing Kuo; Michael Lee; Elitza Belcheva; Matthew Spaits; Rosa Grenha; Michelle C Maguire; Jeffrey L Frost; Kathryn Wang; Steven D Briscoe; Mark J Alexander; Brantley R Herrin; Roselyne Castonguay; R Scott Pearsall; Patrick Andre; Paul B Yu; Ravindra Kumar; Gang Li
Journal:  Sci Rep       Date:  2022-05-12       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.